Immunemonitoring of patients scheduled for liver transplantation and resectio

Recruiting

• Conditions: C22.0; Liver cell carcinoma

• Registration Number: DRKS00013567
• Lead Sponsor: Klinikum der LMU München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-08-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Informed Consent, at least 18y of age, no previous Treatment, scheduled for resection or transplantation

Exclusion Criteria

No consent, underaged, pregnant, prior treatment 6 weeks prioir inclusion in study, other malignancies, infection, prior treatment in the liver 6 weeks prioir inclusion in study (e.g. TACE, RFA etc.)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Aim of this study is to identify immunological markers for risk stratification of HCC patients

Secondary Outcome Measures

Name	Time	Method
With sttistical modelling we want to calculate the sensistivity and specificity for the newly discovered markers